Biotech penny stocks can be a great investment. Especially if you want big wins in an industry that just keeps growing.
Biotechnology is a strong industry in itself. She is constantly on the lookout for new solutions to endless problems in the healthcare world. And it is even more necessary when it comes to hospitals and surgeries. We will do anything to save the life of a loved one … Or better our own.
As for stocks quoted in cents, they offer enormous potential for making money. Exercise due diligence. Find great companies with strong leadership or an incredibly useful product. Or even a young company with a promising therapeutic pipeline. Once you find good ones and invest, it is possible to make a lot of money.
That being said, stocks quoted in cents are very volatile. It means that you can earn a lot. It also means that it is possible to lose your entire investment. And sometimes you can lose it in a matter of days or minutes. They are an inherently risky investment.
If you are not willing to lose your investment, penny stocks may not be right for you.
However, if you want to invest in stocks listed in pennies, educate yourself. Learn how to do your due diligence. Protect your investment dollars with diversification. This helps because if one of the stocks in your portfolio is a dud, it won’t bring your entire portfolio down.
Usually, even if you do a little bit of due diligence, you won’t waste your money. But businesses are very complex creatures. It only takes one little thing for the stock to dive in, taking your money with it. So do your homework … Even on those companies that I present to you.
Best Biotech Penny Stocks
- Seelos Therapeutics (Nasdaq: SEEL)
- NanoVibronix Inc. (Nasdaq: NAOV)
- ReShape Lifesciences Inc. (Nasdaq: RSLS)
- Soligenix Inc. (Nasdaq: SNGX)
- Transcode Therapeutics (Nasdaq: RNAZ)
- Citius Pharmaceuticals (Nasdaq: CTXR)
- electroCore (Nasdaq: ECOR)
Biotech Penny Stocks to Buy
Seelos Therapeutics is a clinical stage company in the biopharmaceutical world. He focuses on the development of therapies for disorders of the central nervous system. He also focuses on finding treatments and cures for rare diseases.
His stock appears to be picking up after a long, sleepy bear run. From 2000 – when the stock peaked at around $ 100,000 per share – until now everything has been going down. It fell to less than a dollar, sometimes trading around $ 0.50. But from January 2021 to today, it has apparently broken that bearish cycle. In April 2021, it peaked at $ 6.25.
At the time of this writing, it is trading at just over $ 2. So it is still much higher than it has been for years. Even after a downward correction. And now it looks like Seelos is entering a bull run. Although still highly speculative, Seelos is still one of the most compelling biotech penny stocks.
NanoVibronix has strong financial results for the second quarter of 2021. Revenue increased by 18.22% compared to the second quarter of last year. The net result is up 85.38%. And the net profit margin increased by 87.63%.
This action also seems to be making a comeback after a long bear spell. In September 2020, prices were very low at $ 0.60. But, the bear seemed to be slowing down from its downward momentum. This is the first step in becoming a bull.
Then it erupted and climbed in February to $ 1.47. It came down again, then climbed to $ 3.10 at the end of August. Right now it’s in a downward correction. But it’s still trading at $ 1.64 as of this writing. So he definitely broke his long bear run.
NanoVibronix produces ultrasound technology that sends out acoustic waves. These waves repair tissue and help shrink tissue formed by catheter infections. While this is a rather niche area to specialize in, its solid financials make it one of the strongest biotech penny stocks on the market today.
ReShape Lifesciences Inc.
ReShape recorded a good increase in its net profit margin compared to the second quarter of last year. It increased by 47.78%. While it’s still down 110% overall, it’s a good step forward.
This is another stock that has been in a bear race for a long time. Recently though, he’s had a nice little spike. And it merged with Obalon Therapeutics in June. This could therefore be a prescription for certain gains in the course of its action.
ReShape is a company specializing in weight loss solutions. Its website features a unique product. It’s a pill that you swallow. Inside there is a balloon filled with gas. And explodes in the stomach. It is the first and only of its kind.
They also offer a vest and an abdominal band to help with weight loss. As we all know, the United States is not the leanest nation. The alarm on the obesity epidemic has been ringing for years. If ReShape can capture some of the market share of the diet craze, it could be the most explosive biotech penny stock on the list.
Soligenix is ââan advanced stage biopharmaceutical company. It specializes in the development and commercialization of solutions for rare diseases in unsatisfied markets. These include lymphoma and Crohn’s disease.
The Soligenix stock has been stable for some time. But, this stock has mixed reviews and forecasts. And it targets cancer and other rare diseases. Not only that, but he offers solutions for them.
This is more of a long term take if you want to see gains. The stock could go up. But the stock chart itself doesn’t show any major buying signs. However, it might start producing returns in the future. And if the treatment for lymphoma gets out of phase 3 trials and hits the market soon, it might not be one of the biotech penny stocks for long.
Transcode is another stock that has only been on the market for a few months. It is listed in July. Then it had its little downward correction that most companies see when stocks are first listed. But it has already seen a slight price hike from $ 2.43 to $ 3.66 in September. This follows news that net profit was up 2,278.42% from a year ago for the second quarter.
Transcode uses RNA oncology to fight cancer. He has created a marketing pipeline that strives to get products to market quickly. And he uses the decades of medical expertise and financial knowledge he has on the staff to do this. Keep in mind that this is a relatively new business. Most of the therapies in its pipeline are still in the preclinical stage. But if any of them meet with quick success, Transcode could find itself pulled out of the penny stock dispute.
Citius is another stock that has been in sleepy bear mode for years. In June 2021 however, it saw a nice little price increase. This happened after he lifted and broke the bear cycle.
That being said, its price has been corrected. But it is still much higher than it was before the hike. For me, it’s a buy signal. This shows that he is about to reappear … Or at least to slowly rise a little more.
Citius focuses on the commercialization of critical care products. Some of the current therapies include anti-infectives in cancer care. Also, stem cell therapy and unusual prescription products. Its bioresorbable antimicrobial shell has the potential to be the first product approved by the FDA to prevent infections in people having to deal with post-mastectomy breast implants. While there is no direct timeline for approval, if and when it does hit the market, it could be a major catalyst for this biotech penny stock.
electroCore specializes in the treatment of a nerve in the human body: the vagus nerve. It is the longest cranial nerve in the body. It interacts with the heart, lungs and digestive tract.
When this nerve is stimulated, it can help heal various ailments. And because the vagus nerve touches so many different areas, there are almost endless conditions that the electroCore product can treat. He’s working on therapies to treat or prevent stroke, Parkinson’s disease, and post-traumatic stress disorder, to name a few. The potential market for its treatments is therefore enormous.
electroCore also allows patients to self-administer low doses using their product. Those already on the market can help treat respiratory and airway diseases and intestinal problems. It also treats neurological problems, cluster headaches and migraines. There is much to be excited about in the electroCore pipeline. And that makes them one of the biotech penny stocks to watch.
The Final Word on These Biotech Penny Stocks to Buy
The biotechnology industry is full of potential. And these biotech penny stocks are just the tip of the scalpel. If you would like to learn more about other investment opportunities in the healthcare industry and beyond, we suggest you subscribe to Rich retirement. In this free electronic newsletter, investment expert Marc Lichtenfeld helps his readers uncover the hidden gems of the biotech industry. And all you have to do is enter your email address in the box below to get started.
About Vanessa Adelman
Vanessa Adelman graduated with an interdisciplinary degree. She specialized in entrepreneurship, painting, music and cinema. Shortly thereafter, she received an editorial mentorship with Mark Morgan Ford. Then she got her AWAI verification. Now Vanessa is freelance in the direct financial response industry. She has been investing since 2016. In her spare time, she enjoys books on money and wealth. She enjoys being with her boyfriend, hunting, fishing and having outdoor adventures.